Dr. SERKAN ERKANLI

Gynecologic Oncology , Gynecology and Obstetrics

Education

• 2011Medical Specialization Board Gynecological Oncology Surgery
• 2011IRCAD Robotic Surgery Strasbourg, France
• 2007Başkent University Faculty of Medicine, Department of Obstetrics and Gynecology, Associate Professor
• 2005St. Stephen Hospital, Department of Gynecological Oncology, Budapest, Hungary, Fellow
• 2003Centre Oscar Lambret Cancer Center, Lille, France, Fellow
• 2000 – 2001University of Southern California (USC),Keck School of Medicine Women”s and Children”s Hospital,Jinekolojik Onkoloji Bölümü,Norris Cancer Institute, Los Angeles, California, ABD, Visiting Fellow
• 1999Marmara University Faculty of Medicine Department of Obstetrics and Gynaecology
• 1988 – 1995Istanbul University Cerrahpasa Medical Faculty
• 1981 – 1988Kadıköy Anatolian High School

Experience

• 2021Acıbadem Mehmet Ali Aydınlar University / Head of Gynecological Oncology Surgery Department
• 2010Acıbadem Health Group
• 2002 – 2010Başkent University Faculty of Medicine, Department of Obstetrics and Gynecology, Adana
• 2001 – 2002Bahat Private Hospital, Istanbul
• 1995 – 1999Marmara University Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul

Memberships

• Turkish Medical Association
• Turkish Gynecological Oncology Society (TRSGO)
• Cervical Pathology and Colposcopy Association
• European Society of Gynecological Oncology (ESGO)
• International Gynecologic Cancer Society (IGSC)
• Turkish Gynecology and Obstetrics Association
• Minimally Invasive Gynecology Association
• Minimally Invasive Gynecologic Oncology Association
• Robotic Surgery Association

PUBLICATIONS

• Fertility sparing therapy in young women with endometrial cancer: 2010 Update.Int. J Gynecol. Cancer 20,1170-1187, 2010 Erkanli S., Ayhan A.
• Maspin Overexpression Correlates With Increased Expression of Vascular Endothelial Growth factors A, C, and D in Human Ovarian Carcinoma.Bolat F., Gumurdulu D., Erkanli S., Kayaselcuk F., Zeren H., Vardar MA, Kuscu E. Pathology Research and Practice 204(6):379-87, 2008
• How best is to discontinue postmenopausal hormone therapy: Immediate or tapered?Aslan E., Bagis T., Kilicdag EB, Tarim E., Erkanli S., Kuscu E. Maturitas. 56(1),78-83, 2007
• COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.Erkanli S. , Bolat F., Kayaselcuk F., Demirhan B., Kuscu E. Gynecol. Oncol. 104(2),320-325, 2007
• Impact of morbid obesity in surgical management of endometrial cancer: surgical morbidity, clinical and pathological aspects.[ PMC free article ] [ PubMed ] [ Cross Ref ] 14. Erkanli S, Kayaselcuk F, Bagis T, Kuscu E. Eur. J. Gynaecol Oncol. 27(4),401-404, 2006
• Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium.Erkanli S., Kayaselcuk F., Kuscu E., Bagis T., Bolat F., Haberal A., Demirhan B. Int. J. Gynecol. Cancer. 16(3),1412-1418, 2006
• Expression of cyclin H in normal and cancerous endometrium, its correlation with other cyclins, and association with clinicopathologic parameters.Kayaselcuk F., Erkanli S., Bolat F., Seydaoglu G., Kuscu E., Demirhan B. Int. J. Gynecol. Cancer. 16(1):402-408, 2006
• Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.Erkanli S., Kayaselcuk F., Kuscu E., Bolat F., Sakalli H., Haberal A. Breast. 15(4),558-561, 2006
• HPV and p53 expression in epithelial ovarian carcinoma.Kuscu E., Ozdemir BH, Erkanli S., Haberal A. Eur. J. Gynaecol. Oncol. 26(6),642-645, 2005
• Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.Kilicdag EB, Bagis T., Zeyneloglu HB, Tarim E., Aslan E., Haydardedeoglu B., Erkanli S. Hum. Reprod. 20(4),894-899, 2005